Updated hourlyHourly refreshTue, Oct 27, 2026
Press Release Database
Recent press releases, indexed by topic.
Sustainability · Marketing & advertising
LONDON, UNITED KINGDOM, October 25, 2026 / EINPresswire.com / -- Prof. Dr. Shabnam (Shery) Delfani, internationally recognised environmental scientist, professor and geopolitical analyst, has been awarded the International Recognition Award at the Influencer Magazine Awards (E3) on October 25, 2026, honouring her extraordinary contributions to climate change modelling, sustainability, water diplomacy and internationa
Oct 25 · 06:45·EIN Presswire
Finance · Healthcare
Media Release COPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor … Continue reading "Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer"
Oct 25 · 06:15·PressReach
Biotech & pharma
In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acceptable safety profile and early signals of efficacy 41.7% (10/24) overall response rate (ORR) per RECIST 1.1, including 4 complete responses 75% (18/24) disease control rate (DCR) … Continue reading "NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma"
Oct 25 · 06:15·PressReach
Healthcare · Biotech & pharma
Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmark Disease control rate of 100% across all response-evaluable patients receiving a starting dose of ≥450 mg, with no disease progression and no treatment discontinuations due to TRAEs Data informed FDA-aligned dose and regimen selection for upcoming PEDESTAL … Continue reading "Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors"
Oct 25 · 06:15·PressReach
Finance · Jobs & workplace
VANCOUVER, British Columbia, Oct. 24, 2026 — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) announced today that strike action by United Steelworkers (USW) Local 7619 has commenced at Teck's Highland Valley Copper (HVC) Operations in B.C. Operations are currently continuing at a reduced capacity. The impact on overall production will … Continue reading "Teck Provides Update on Highland Valley Copper Operations"
Oct 25 · 06:15·PressReach
Biotech & pharma
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027 200 mg and 600 mg doses have been generally well-tolerated Separate MCD case study described three-year steroid-free remission following budoprutug treatment, supporting … Continue reading "Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026"
Oct 25 · 06:15·PressReach
Insurance · Marketing & advertising
HONG KONG and SHANGHAI, Oct. 25, 2026 -- The Seminar on International Communication of Chinese and Foreign Enterprises' Green Development and Global Contributions was held at the Ping An Finance Center in Shenzhen on October 23. Hosted by the China Public Relations...
Oct 25 · 06:01·PR Newswire
Finance · Industrial
SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune,...
Oct 25 · 06:00·PR Newswire
Finance · Industrial
SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune,...
Oct 25 · 06:00·PR Newswire
SaaS · Media
-- XUANNOVA held a product presentation in Los Angeles, introducing its approach to classical literature, traditional cultural knowledge, and multilingual digital learning. Designed for people interested in Eastern culture, the platform brings reference materials, thematic content, and online study tools together in one place. As digital formats create new opportunities for cultural exchange, XUANNOVA aims to make tr
Oct 25 · 05:21·MarketersMEDIA
In the wire
-- During Chery International User Summit 2026, CHERY held a family parking challenge carnival at Squirrel Town. Centred on SIVP (Super Intelligent Valet Parking), it combined a parking workshop, scenario challenges and hands-on experiences, showing global guests how intelligent parking can save families time and effort. A Parking Technology Class Introduces SIVP as the Latest Expression of “Technology. For Family” A
Oct 25 · 05:21·MarketersMEDIA
Internet & apps · Consumer goods
Chris Gibson Live passes 1 million YouTube subscribers as the licensed esthetician expands skincare and wellness brands. -- Chris Gibson, licensed esthetician, author, and digital skincare educator known to audiences as America’s Holistic Esthetician, has announced that his YouTube channel, Chris Gibson Live , has surpassed 1 million subscribers. The milestone follows a period of rapid audience growth, including more
Oct 25 · 05:11·MarketersMEDIA